In 300-some words, Pfizer released a tantalizing figure describing a glimpse into the results of its Phase 3 clinical trial for a coronavirus vaccine. The first batch of data suggests the vaccine is about 90% effective, the drug maker’s CEO Albert Bourla wrote, a rate far exceeding the expectations of even its own researchers.
↧